The BalancedInvestor Club

MIRA Market Analysis

Overview

Fundamentals

P/E ratio—
EPS (TTM)$-1.350.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$43.7MMicro cap

Valuation

Forward P/E
—
PEG ratio
—
P/B
4.21
P/S (TTM)
—
EV/EBITDA
-1.45

Profitability & growth

ROE (TTM)
-165.9%
Operating margin
0.0%
Revenue growth YoY
0.0%
Dividend yield
—
Beta
1.94
Last earnings
Feb 25, 2026 · Estimate $-0.08 · Reported $-0.14
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About MIRA Pharmaceuticals, Inc. Common Stock

MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company. The company is headquartered in Baltimore, Maryland.

Classification

Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
1200 BRICKELL AVENUE, MIAMI, FL
Fiscal year end
December
Latest quarter
Dec 31, 2025
Market cap$43.7M
Shares outstanding$42.0M
52W high$2.45
52W low$0.90

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer